Moving pan-cancer studies from basic research toward the clinic
Although all cancers share common hallmarks, we have long realized that there is no silver-
bullet treatment for the disease. Many clinical oncologists specialize in a single cancer type …
bullet treatment for the disease. Many clinical oncologists specialize in a single cancer type …
Tumor mutational burden as a predictor of immunotherapy response: is more always better?
Immune checkpoint inhibitors, including antibodies that block programmed cell death protein-
1 (PD-1) and PD-L1, have transformed the management of many cancers. However, the …
1 (PD-1) and PD-L1, have transformed the management of many cancers. However, the …
TMB in NSCLC: a broken dream?
S Bravaccini, G Bronte, P Ulivi - International journal of molecular …, 2021 - mdpi.com
Although immune checkpoint inhibitors have changed the treatment paradigm of a variety of
cancers, including non-small-cell lung cancer, not all patients respond to immunotherapy in …
cancers, including non-small-cell lung cancer, not all patients respond to immunotherapy in …
[HTML][HTML] Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: Pembrolizumab versus chemotherapy for …
Background We evaluated whether tissue tumor mutational burden (tTMB) and STK11,
KEAP1, and KRAS mutations have clinical utility as biomarkers for pembrolizumab …
KEAP1, and KRAS mutations have clinical utility as biomarkers for pembrolizumab …
A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape
Background Immune checkpoint inhibitor (ICI) therapy has revolutionized the treatment of
many cancers. However, the limited population that benefits from ICI therapy makes it …
many cancers. However, the limited population that benefits from ICI therapy makes it …
Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT …
Summary Background The NIBIT-MESO-1 study demonstrated the efficacy and safety of
tremelimumab combined with durvalumab in patient with unresectable mesothelioma …
tremelimumab combined with durvalumab in patient with unresectable mesothelioma …
PD-L1 expression is significantly associated with tumor mutation burden and microsatellite instability score
Simple Summary Biomarkers for predicting the response to immune checkpoint blockade
(ICB) includes programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) …
(ICB) includes programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) …
Panels and models for accurate prediction of tumor mutation burden in tumor samples
E Martínez-Pérez, MA Molina-Vila… - NPJ Precision …, 2021 - nature.com
Immune checkpoint blockade (ICB) is becoming standard-of-care in many types of human
malignancies, but patient selection is still imperfect. Tumor mutation burden (TMB) is being …
malignancies, but patient selection is still imperfect. Tumor mutation burden (TMB) is being …
Prevalence and landscape of actionable genomic alterations in renal cell carcinoma
K Attalla, RG DiNatale, PM Rappold, CJ Fong… - Clinical Cancer …, 2021 - AACR
Purpose: We report our experience with next-generation sequencing to characterize the
landscape of actionable genomic alterations in renal cell carcinoma (RCC). Experimental …
landscape of actionable genomic alterations in renal cell carcinoma (RCC). Experimental …
[HTML][HTML] RNA-seq reveals differences in expressed tumor mutation burden in colorectal and endometrial cancers with and without defective DNA-mismatch repair
MA DiGuardo, JI Davila, RA Jackson, AA Nair… - The Journal of Molecular …, 2021 - Elsevier
Tumor mutation burden (TMB) is an emerging biomarker of immunotherapy response. RNA
sequencing in FFPE tissue samples was used for determining TMB in microsatellite-stable …
sequencing in FFPE tissue samples was used for determining TMB in microsatellite-stable …